Compare Badger Meter Inc (BMI) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Badger Meter (BMI) trades at $140.12, down 2.82% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company reported $917M revenue and $142M net income for 2025, with strong profitability margins but recent earnings misses in Q4 2025 and Q1 2026. A securities class action lawsuit filed in July 2026 adds significant near-term uncertainty, though analyst consensus remains a Buy with a $144.60 price target.

The stock faces headwinds from legal risks and earnings volatility, but solid fundamentals and analyst support suggest potential recovery if legal concerns subside. Investors should weigh the high valuation multiples against operational strength and monitor lawsuit developments closely for directional cues.

Regeneron (REGN) trades at $663.09, down slightly by 0.22% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability, with a net income margin of 29.65% and consistent earnings beats in recent quarters. Recent positive news includes FDA and EMA acceptance of its cemdisiran application for gMG and selection for an FDA pilot program to accelerate manufacturing reviews, highlighting operational momentum.

The outlook remains positive given analyst consensus with a $764.50 price target and no sell ratings, though risks include regulatory hurdles and competitive pressures in biotech. Earnings growth and pipeline advancements are key catalysts, but investors should weigh high RSI levels suggesting potential near-term overbought conditions against strong fundamental performance.